Navigation Links
OncoGenex Reports First Quarter Financial Results
Date:5/7/2009

Conference Call on Thursday, May 7, 2009 at 4:30 p.m. Eastern Time

BOTHELL, WA, and VANCOUVER, May 7 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. ("OncoGenex" or the "Company") (NASDAQ: OGXI) today reported unaudited financial results for the three months ended March 31, 2009 and reviewed the Company's highlights for the first quarter of 2009.

The following consolidated results reflect the operations of OncoGenex Technologies Inc. ("OncoGenex Technologies") prior to the August 21, 2008 reverse takeover of Sonus Pharmaceuticals, Inc. ("Sonus"), and the consolidated results of OncoGenex thereafter.

The loss attributable to common shareholders for the first quarter ended March 31, 2009 was $2.4 million which was consistent with the loss of $2.4 million in the corresponding period of 2008.

Research and development expenses for the first quarter ended March 31, 2009 were $1.7 million, compared to $0.9 million in the corresponding period of 2008. The increases in 2009 were primarily due to manufacturing costs incurred in the first quarter of 2009 associated with the development of our product candidate OGX-427, an increase in employee expenses and higher facility costs resulting from the reverse takeover of Sonus. Reducing the expenses in the first quarter of 2008 was a Scientific Research and Development (SRED) claim, which offset R&D expenses in that period. The SRED program is a Canadian federal tax incentive program that encourages Canadian businesses to conduct research and development in Canada. As OncoGenex Technologies became an affiliate of a public company as a result of the reverse takeover, SRED claims can now only be applied against taxes payable.

General and administrative expenses for the first quarter ended March 31, 2009 were $0.8 million, compared to $0.6 million in the corresponding perio
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
2. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
3. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
4. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
5. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
6. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
7. OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference
8. OncoGenex Reports Third Quarter Financial Results
9. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... NH (PRWEB) , ... July 30, 2015 , ... ... homogenizer for advanced fluid applications and designed for continuous operation up to 1500 ... and sterilization-in-place, ensuring safety, efficiency, and preventing toxic contamination. , The Pony™ NS2006L ...
(Date:7/29/2015)... (Q2 2015: +14% CER / 20% of sales) led the regional performance ... , as well as solid contributions from Korea, India ... Middle East / Africa (Q2 ... , Turkey and the United Kingdom ... 11%, excluding U.S. HPV sales, on demand across all customer classes. The top ...
(Date:7/29/2015)... July 29, 2015 ... the addition of the "Global Biosimilars Market, ... The Global Biosimilars Market, 2015 - ... rapidly growing biosimilars market. With the blockbuster biologics ... minimize costs, biosimilars are being viewed as viable ...
(Date:7/29/2015)... , July 29, 2015  Indivior PLC (LON: ... for naloxone nasal spray was accepted and received Priority ... for the treatment of opioid overdose. This naloxone nasal ... specially formulated for optimal absorption into the nasal mucosa. ... minimal training so individuals may be better equipped to ...
Breaking Biology Technology:GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2QIAGEN Reports Results for Second Quarter and First Half of 2015 2QIAGEN Reports Results for Second Quarter and First Half of 2015 3QIAGEN Reports Results for Second Quarter and First Half of 2015 4QIAGEN Reports Results for Second Quarter and First Half of 2015 5QIAGEN Reports Results for Second Quarter and First Half of 2015 6QIAGEN Reports Results for Second Quarter and First Half of 2015 7QIAGEN Reports Results for Second Quarter and First Half of 2015 8QIAGEN Reports Results for Second Quarter and First Half of 2015 9QIAGEN Reports Results for Second Quarter and First Half of 2015 10Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 4Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 5
... Imagine an LED light with 20 times the efficiency ... transmit, and store data 100 times faster than those we ... we could turn waste heat into electricity, or improve the ... more accessible? The (IEE) at the University of ...
... Inc., a company dedicated to advancing orthopedic care ... that it has secured a $2M investment from ... chairman of Liberty Media Corporation. In addition to ... research, the investment will help support the national ...
... 2012   USHIFU, LLC (US HIFU), a world leader ... technologies, announced today that Mark Carol, MD, has ... officer. With more than 25 years of clinical ... will focus on continued development of the company,s ...
Cached Biology Technology:Oracle chairman Jeff Henley makes $50 million gift to UC Santa Barbara 2Oracle chairman Jeff Henley makes $50 million gift to UC Santa Barbara 3Oracle chairman Jeff Henley makes $50 million gift to UC Santa Barbara 4Regenerative Sciences Receives $2M Investment for Orthopedic Stem Cell Initiatives 2US HIFU Adds Mark Carol, MD, As Chief Development Officer 2US HIFU Adds Mark Carol, MD, As Chief Development Officer 3US HIFU Adds Mark Carol, MD, As Chief Development Officer 4
(Date:7/13/2015)... JOSE, Calif. , July 13, 2015 /PRNewswire/ ... leading developer of human interface solutions, today announced ... generation touch and display driver integration (TDDI) product ... is the first to combine Synaptics , ... with proven display driver technology developed in the ...
(Date:7/9/2015)... 9, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced a new Match-in-Sensor™ ... hardware encapsulated fingerprint sensor and matching solution. ... literally off the grid, isolating fingerprint image ... the fingerprint sensor to provide ultimate protection ...
(Date:7/7/2015)... , June 30, 2015 ... announced the addition of the "Capacitive Fingerprint ... To this date, fingerprint sensing technology ... and fingerprint sensors are well developed. This patent ... technology. The domain of capacitive fingerprint ...
Breaking Biology News(10 mins):Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2
... MUHC have announced Quebec's first successful combined heart/liver transplant. ... from the Institut de cardiologie de Quebec (l'hôpital Laval) ... and liver during a 6-hour operation on April 14, ... procedure involved 15 physicians, surgeons and other health care ...
... used hybridization to transfer useful traits between species. ... aid? In a new study in the June ... University and Rice University), Rebecca A. Randell (Indiana ... how spontaneous hybridization ?known as adaptive trait introgression ...
... astonishing ability to apparently transform into any kind of cell ... with their surroundings - even when they are outside of ... report. , Using an animal model of embryonic stem cell ... answer one of the most fundamental questions in science - ...
Cached Biology News:MUHC announces a transplant first in Quebec 2Medium is the message for stem cells in search of identities 2Medium is the message for stem cells in search of identities 3
(3-[125I]iodotyrosyl26)Galanin, porcine, 370 kBq, 10 uCi. Category: IODINE LIGANDS....
Homo sapiens postsynaptic protein CRIPT Antigen: Recombinant Protein...
Immunogen: Synthetic peptide based on the sequence: SPSSGPSLTADSMWR Storage: -20 C, Avoid Freeze/Thaw Cycles...
Human beta IG-H3 MAb (Clone 348506) Keywords: BIGH3, betaIG-H3 Protein Family: Extracellular Matrix Molecules...
Biology Products: